Products for Research Use Only
RegisterLogin

Vorinostat-d5

CAT: 0804-HY-115412Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-115412Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Vorinostat-d5 (SAHA-d5) is the deuterium labeled Vorinostat. Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC7 (Class II) and HDAC11 (Class IV), with ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis[1][4]. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV) -18 DNA amplification[7].
CAS Number
1132749-48-4
Product Name Alternative
SAHA-d5; Suberoylanilide hydroxamic acid-d5
UNSPSC
12352005
Hazard Statement
H319
Target
Apoptosis; Autophagy; Filovirus; HDAC; HPV; Mitophagy
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics
Field of Research
Cancer; Infection
Purity
99.0
Solubility
10 mM in DMSO
Smiles
O=C(NO)CCCCCCC(NC1=C([2H])C([2H])=C([2H])C([2H])=C1[2H])=O
Molecular Formula
C14H15D5N2O3
Molecular Weight
269.35
Precautions
P264-P280-P305+P351+P338
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Hrzenjak A et al. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer. 2010 Mar 4;9:49.; Lautz TB, et al. The effect of vorinostat on the development of resistance to NSC 123127 in neuroblastoma. PLoS One. 2012;7 (7) :e40816.; Richon VM, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A. 1998 Mar 17;95 (6) :3003-7.; Xu WS, et al. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007 Aug 13;26 (37) :5541-52.; Pérez-Cañamás A, et al. Sphingomyelin-induced inhibition of the plasma membrane calcium ATPase causes neurodegeneration in type A Niemann-Pick disease. Mol Psychiatry. 2017 May;22 (5) :711-723.; Wang J, et al. Snail determines the therapeutic response to mTOR kinase inhibitors by transcriptional repression of 4E-BP1. Nat Commun. 2017 Dec 20;8 (1) :2207.; Banerjee NS, et al. Vorinostat, a pan-HDAC inhibitor, abrogates productive HPV-18 DNA amplification. Proc Natl Acad Sci U S A. 2018 Nov 20;115 (47) :E11138-E11147.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-10221-01Vorinostat
HY-10221GVorinostat (GMP)
HY-10221R-01Vorinostat (Standard)
HY-151913S-01Sebuthylazine-d5 (ethyl-d5)
HY-W717221Medetomidine-d5 (d5-Major)
HY-133171AS-01(S) -Norfluoxetine-d5 (phenyl-d5)
HY-151910S1(±) -Fluoxetine-d5 Oxalate (phenyl-d5)
HY-W758414Phoxim-d5 (phenyl-d5) (mixture of isomers)
HY-133171AS1-01(R) -Norfluoxetine-d5 Phthalimide (Phenyl-d5)
HY-113215SAllotetrahydrocortisol-d5

Alternative Products

CatalogName
AR-V01854-01Vorinostat-d5
MBS131055-01Vorinostat
S7990-01ASuberoylanilide-d5 Hydroxamic Acid (SAHA-d5, N-Hydroxy-N’-phenyl-d5-octanediamide, Zolinza-d5, Vorinostat-d5)
MBS6042326-01Suberoylanilide-d5 Hydroxamic Acid (SAHA-d5, N-Hydroxy-N'-phenyl-d5-octanediamide, Zolinza-d5, Vorinostat-d5)
MBS386454-01Vorinostat (SAHA)
MBS808063-01SAHA (Vorinostat)
A10979-200Vorinostat 200mg

Popular Products